Cargando…
A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients
BACKGROUND: DNA adducts, covalent modifications to DNA due to exposure to specific carcinogens, cause the mispairing of DNA bases, which ultimately results in DNA mutations. DNA methylation in the promoter region, another type of DNA base modification, alters the DNA transcription process, and has b...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638144/ https://www.ncbi.nlm.nih.gov/pubmed/34852853 http://dx.doi.org/10.1186/s41021-021-00228-9 |
_version_ | 1784608892562440192 |
---|---|
author | Matsushita, Yuto Iwashita, Yuji Ohtsuka, Shunsuke Ohnishi, Ippei Yamashita, Takashi Miyake, Hideaki Sugimura, Haruhiko |
author_facet | Matsushita, Yuto Iwashita, Yuji Ohtsuka, Shunsuke Ohnishi, Ippei Yamashita, Takashi Miyake, Hideaki Sugimura, Haruhiko |
author_sort | Matsushita, Yuto |
collection | PubMed |
description | BACKGROUND: DNA adducts, covalent modifications to DNA due to exposure to specific carcinogens, cause the mispairing of DNA bases, which ultimately results in DNA mutations. DNA methylation in the promoter region, another type of DNA base modification, alters the DNA transcription process, and has been implicated in carcinogenesis in humans due to the down-regulation of tumor suppressor genes. Difficulties are associated with demonstrating the existence of DNA adducts or chemically modified bases in the human urological system. Apart from aristolochic acid-DNA adducts, which cause urothelial carcinoma and endemic nephropathy in a particular geographical area (Balkan), limited information is currently available on DNA adduct profiles in renal cell carcinoma and upper urinary tract urothelial carcinoma, including renal pelvic cancer and ureteral cancer. METHOD: To elucidate the significance of DNA adducts in carcinogenesis in the urothelial system, we investigated 53 DNA adducts in the non-tumoral renal parenchyma and non-tumoral renal pelvis of patients with renal cell carcinoma, upper urinary tract urothelial carcinoma, and other diseases using liquid chromatography coupled with tandem mass spectrometry. A comparative analysis of tissue types, the status of malignancy, and clinical characteristics, including lifestyle factors, was performed. RESULTS: C5-Methyl-2′-deoxycytidine, C5-hydroxymethyl-2′-deoxycytidine (5hmdC), C5-formyl-2′-deoxycytidine, 2′-deoxyinosine, C8-oxo-2′-deoxyadenosine, and C8-oxo-2′-deoxyguanosine (8-OHdG) were detected in the renal parenchyma and renal pelvis. 8-OHdG was more frequently detected in the renal pelvis than in the renal cortex and medulla (p = 0.048 and p = 0.038, respectively). 5hmdC levels were significantly lower in the renal pelvis of urothelial carcinoma patients (n = 10) than in the urothelium of patients without urothelial carcinoma (n = 15) (p = 0.010). Regarding 5hmdC levels in the renal cortex and medulla, Spearman’s rank correlation test revealed a negative correlation between age and 5hmdC levels (r = − 0.46, p = 0.018 and r = − 0.45, p = 0.042, respectively). CONCLUSIONS: The present results revealed a reduction of 5hmdC levels in the non-tumoral urinary tract mucosa of patients with upper urinary tract urothelial carcinoma. Therefore, the urothelial cell epithelia of patients with upper urinary tract cancer, even in non-cancerous areas, may be predisposed to urothelial cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41021-021-00228-9. |
format | Online Article Text |
id | pubmed-8638144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86381442021-12-02 A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients Matsushita, Yuto Iwashita, Yuji Ohtsuka, Shunsuke Ohnishi, Ippei Yamashita, Takashi Miyake, Hideaki Sugimura, Haruhiko Genes Environ Research BACKGROUND: DNA adducts, covalent modifications to DNA due to exposure to specific carcinogens, cause the mispairing of DNA bases, which ultimately results in DNA mutations. DNA methylation in the promoter region, another type of DNA base modification, alters the DNA transcription process, and has been implicated in carcinogenesis in humans due to the down-regulation of tumor suppressor genes. Difficulties are associated with demonstrating the existence of DNA adducts or chemically modified bases in the human urological system. Apart from aristolochic acid-DNA adducts, which cause urothelial carcinoma and endemic nephropathy in a particular geographical area (Balkan), limited information is currently available on DNA adduct profiles in renal cell carcinoma and upper urinary tract urothelial carcinoma, including renal pelvic cancer and ureteral cancer. METHOD: To elucidate the significance of DNA adducts in carcinogenesis in the urothelial system, we investigated 53 DNA adducts in the non-tumoral renal parenchyma and non-tumoral renal pelvis of patients with renal cell carcinoma, upper urinary tract urothelial carcinoma, and other diseases using liquid chromatography coupled with tandem mass spectrometry. A comparative analysis of tissue types, the status of malignancy, and clinical characteristics, including lifestyle factors, was performed. RESULTS: C5-Methyl-2′-deoxycytidine, C5-hydroxymethyl-2′-deoxycytidine (5hmdC), C5-formyl-2′-deoxycytidine, 2′-deoxyinosine, C8-oxo-2′-deoxyadenosine, and C8-oxo-2′-deoxyguanosine (8-OHdG) were detected in the renal parenchyma and renal pelvis. 8-OHdG was more frequently detected in the renal pelvis than in the renal cortex and medulla (p = 0.048 and p = 0.038, respectively). 5hmdC levels were significantly lower in the renal pelvis of urothelial carcinoma patients (n = 10) than in the urothelium of patients without urothelial carcinoma (n = 15) (p = 0.010). Regarding 5hmdC levels in the renal cortex and medulla, Spearman’s rank correlation test revealed a negative correlation between age and 5hmdC levels (r = − 0.46, p = 0.018 and r = − 0.45, p = 0.042, respectively). CONCLUSIONS: The present results revealed a reduction of 5hmdC levels in the non-tumoral urinary tract mucosa of patients with upper urinary tract urothelial carcinoma. Therefore, the urothelial cell epithelia of patients with upper urinary tract cancer, even in non-cancerous areas, may be predisposed to urothelial cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41021-021-00228-9. BioMed Central 2021-12-02 /pmc/articles/PMC8638144/ /pubmed/34852853 http://dx.doi.org/10.1186/s41021-021-00228-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Matsushita, Yuto Iwashita, Yuji Ohtsuka, Shunsuke Ohnishi, Ippei Yamashita, Takashi Miyake, Hideaki Sugimura, Haruhiko A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients |
title | A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients |
title_full | A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients |
title_fullStr | A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients |
title_full_unstemmed | A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients |
title_short | A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients |
title_sort | dna adductome analysis revealed a reduction in the global level of c5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638144/ https://www.ncbi.nlm.nih.gov/pubmed/34852853 http://dx.doi.org/10.1186/s41021-021-00228-9 |
work_keys_str_mv | AT matsushitayuto adnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT iwashitayuji adnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT ohtsukashunsuke adnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT ohnishiippei adnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT yamashitatakashi adnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT miyakehideaki adnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT sugimuraharuhiko adnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT matsushitayuto dnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT iwashitayuji dnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT ohtsukashunsuke dnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT ohnishiippei dnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT yamashitatakashi dnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT miyakehideaki dnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients AT sugimuraharuhiko dnaadductomeanalysisrevealedareductioninthegloballevelofc5hydroxymethyl2deoxycytidineinthenontumoralupperurinarytractmucosaofurothelialcarcinomapatients |